Can a cancer drug stop liver tumors from returning after ablation?
NCT ID NCT06248554
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether giving a PD-1 inhibitor (a type of immunotherapy) after microwave ablation can help prevent early-stage liver cancer from coming back. About 200 adults with early liver cancer will receive the drug every three weeks for nine cycles. The main goal is to see if it extends the time before the cancer returns or death occurs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1 inhibitor (a type of immunotherapy drug)
What this could lead to
If it works, this could offer a way to lower the chance of liver cancer coming back after standard ablation treatment.
What could go wrong
This is an early-phase study without a comparison group, so results are uncertain. Immunotherapy can cause side effects like fatigue, rash, or more serious immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
RECRUITINGWuhan, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••